Capricor Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10865 Road to the Cure Ste 150, San Dieg...Phone Number
(858) 727-1755Website
www.capricor.comRevenue
$11.1 MillionStock Symbol
CAPRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative therapeutic approaches by leveraging its expertise in regenerative medicine, cellular therapies, and exosome technology to address significant unmet medical needs.Explore more
Capricor Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Capricor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Capricor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Capricor Therapeutics is spiking on competitors!
Product Launch: Get notified when Capricor Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Capricor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Capricor Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Capricor Therapeutics
Earning: See what the market has to say on Capricor Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Capricor Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Capricor Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Capricor Therapeutics
Compare insights from companies similar to Capricor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$196.1M
201-500
Public
$466M
1990
Bryan RidgellSenior Vice President, Portfolio and Project Management, and Chief of Staff
Company Profile Activity
Activity Insights
Capricor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Capricor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Capricor Therapeutics.
Capricor Therapeutics financials insights
Gather financial insights about Capricor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2024
Private Equity
$35M
Capricor Therapeutics Tech Stack
A closer look at the technologies used by Capricor Therapeutics
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Facilities Relocation/Expansion, Leasing, Manufacturing Operations
Person-Based
Stake & Stock Ownership, Finance
Open Position
Open Position
Open Position
Capricor Therapeutics News & Media
CAPR Investor Alert: Capricor Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
Capricor Therapeutics shareholders who purchased between December 17, 2025 and July 26, 2026 retain specific rights under federal securities law, including the ability to seek recovery of losses tied to an alleged $15.08 per-share decline following FDA briefing documents on the HOPE-3 trial. Capricor Therapeutics shareholders who purchased between December 17, 2025 and July 26, 2026 retain specific rights under federal securities law, including the ability to seek recovery of losses tied to an aCAPR Court News: Capricor Therapeutics Securities Fraud Class Action Filed After Clinical Data Issues and 64% Stock Drop – Contact BFA Law Before September 28
Capricor Therapeutics Securities Fraud Class Action Filed After Clinical Data Issues and 64% Stock Drop – Contact BFA Law Before September 28CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm
Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summary Who: Capricor Therapeutics, Inc. (NASDAQ: CAPR) What: Securities fraud class action lawsuit filed Class Period: December 17, 2025 through July 26, 2026 Deadline to Seek Lead Plaintiff...Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026
Read more news
Top Chemicals & Related Products Companies
See more top companies
Frequently Asked Questions Regarding Capricor Therapeutics
Sign Up For FreeTo access detailed company insights
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative... Read More
